Microbial Carrier-Based Delivery of RHNO1 for Mediating NF-κB Signaling Inhibition to Regulate Proliferation and...

This study aimed to investigate the role and clinical significance of RHNO1 in nonsmall cell lung cancer (NSCLC). By analyzing clinical samples and cell lines, we assessed RHNO1 expression and its correlation with clinicopathological features and patient prognosis, validating its potential as a diagnostic and prognostic biomarker. Furthermore, in vitro and in vivo experiments revealed the functional role of RHNO1 in NSCLC progression and its molecular interaction with the NF-κB signaling pathway, defining the regulatory mechanism of the "RHNO1-NF-κB axis." In parallel, we developed a chitosan-based delivery system (CS-1@RHNO1), which markedly enhanced the loading efficiency and targeting specificity of RHNO1 regulatory agents, enabling precise modulation of the "RHNO1-NF-κB axis." Our findings demonstrate that RHNO1 functions not only as a potential diagnostic and prognostic marker but also as a promising therapeutic target, while the CS-1@RHNO1 system provides a novel strategy for targeted delivery in NSCLC. Collectively, this study offers new theoretical insights and technological advances for understanding NSCLC pathogenesis and developing targeted therapies.